In the world of Oncology, very few have been able to reach the heights attained by Mikhail Blagosklonny. He is an Oncology professor and scientist at the Rosewell Park Cancer Institute in Buffalo, New York and concentrates his study on ageing and cancer. Mikhail’s contribution towards the field of Oncology is immense and unparalleled.He has worked in different places, conducting a lot of research and studies on cancer and therapies. This has enabled Mikhail Blagosklonny to gain a lot of skills hence making him an exceptional professor.Aside from that, he also doubles as the Editor- in-Chief of the Oncotarget publication. This is a weekly medical journal whose primary focus is on ageing. It was launched in 2010. Additionally, Mikhail is the associate editor of therapy and cancer biology. He is also on the editorial board of Cell Differentiation and Death.
Blagosklonny’s Career and Education Background spans across many years of extensive research and study. He holds an MD in Internal Medicine as well as a PhD in Cardiology and Experimental Medicine from the First Pavlov State Medical University of St. Petersburg.He has previously worked with New York Medical College as an associate professor of Medicine and Ordway Research Institute as a senior scientist. In 2009 however, Mikhail became an Oncology Professor at the Roswell Park Cancer Institute.Most of Mikhail’s research focuses on cancer and most importantly anti-aging drugs and cancer therapies. Mikhail is also well known for Rapamycin, a cancer drug that he greatly advocates for. This is because it is said to increase the lifespan of a human being.His extensive research on the drug Rapamycin has included clinical investigations, molecular biology, and cellular biology. Most of his studies are guided by the theory of ageing hyperfunction.
All through his work, his passion for a disease free community stands out. His drive to achieve this is what made him venture into Oncology and research.Mikhail Blagosklonny does not only work with his patients to help them recover, he also engages with other cancer experts to find solutions to the cancer menace. He believes that by putting their brains together, they are able to devolve complex situations and find solutions.Through this, he hopes he will be able to find the cure to cancer. It is clearly bearing fruits as he has made very many strides.Through his publication Oncotarget, Mikhail Blagosklonny has documented his strides and interactions with his peers. This is captured in the peer review segment of the publication.His collaborations with them on different cancer findings has helped many patients experience better treatment.His target for the Oncotarget is to bring many experts and enabling them to work together in the different research situations and subjects.The publication has now seen more and more peers join his team to study how to beat cancer. Not only Oncologists but also neurologists, endocrinologists and other doctors have joined in thanks to the work of Mikhail Blagosklonny and Oncotarget.Medicine students have also been incorporated to learn these new techniques as taught by Mikhail Blagosklonny and make use of it in their practice. They are also able to consult Mikhail Blagosklonny and his team as often as possible.
Eric Lefkofsky, co-founder of a technology company working to battle cancer called Tempus, is the CEO of this company. Alongside his work for Tempus, he has also started his charitable private foundation that works to enhance the lives in many different communities. After graduation from the University of Michigan, he became a professor and author.
Aside from his work at the University of Chicago, Eric Lefkofsky has been working diligently with Tempus to find a cure for cancer. Event though he is 47 years old, Eric wants to find a cure. When his wife came down with the terrible sickness, Eric chose to step in and help start Tempus with the intention of finding a cure.
In several interviews, Eric Lefkofsky has spoken about the difficulties involved with starting a company like this. He was confused about where to even begin with something so difficult and confusing as a cure for cancer. Together, with his friend and business partner, Lefkofsky took a more data-driven approach to attacking the difficulty cancer treatment. They used a machine to look at the different sequences of a patient’s tumor so they could formulate a better plan to treat that specific tumor.
Since fighting cancer has been so personal to Eric, he has found a more driven ideal toward finding the right cure. He has been building a patient library of molecular, Eric Lefkofsky cancer clinical means and then tailoring a system to make this information better for various physicians. Tempus has also teamed up with many different partners and healthcare organizations like many universities and Mayo Clinic. Oncologists also work at these different cancer centers where they send their patients to be put in the clinical library.
This process requires quite a bit of medical knowledge and expertise, but Tempus is not a medical company. Instead, it is a tech company that works with data instead of direct patients. The company has many people already on board, and it is adding new people each week. Tempus measured success will come in the next few years when the research and data begin to pay off by saving lives. Eric Lefkofsky has even gone so far as to say that Tempus might be his most successful company to date.
About Eric Lefkofsky: www.lightbank.com/team/eric-lefkofsky
Eric Lefkofsky is a veteran and extremely successful businessman, having earned around $1.79 billion from a multitude of e-commerce startup. In the past decade he has been founder and owner of Uptake Technologies, Mediaocean, InnerWorkings, Echo Global Logistics public, and Groupon. His most recent company, Tempus, may be his most important company to date. Tempus is an organization that gathers all of the available data into genomic database of cancer. This historic database will enable doctors to drastically improve the treatment of cancer patients in previously unforeseen ways. All of this has been a result of Lefkofsky’s growing realization that although there was a lot of data about cancer treatment out there, doctors did not have at their disposal adequate technology to help them find that data in one place.
And he didn’t just spring up the company all of a sudden. For the ten years preceding its founding, Lefkofsky had been in development of the Institute for Genomics and Systems Biology. Although other companies are presently doing the same thing, Tempus is the most popular in the medical community because it is high-quality but also much more affordable. Although it is still young, Tempus has already partners with a sizeable number of the most prominent hospitals in the country. The research-backed software of Tempus allows doctors compare the DNA profiles of their cancer patients with the profiles of other cancer patients.
This enables these doctors to find effective treatments for their patients when certain treatments have worked well for patients with similar cancer issues. Leftkofsky is so committed to the direction of Tempus that in 2015 he resigned as CEO of Groupon, his most successful company, to focus all of his attention on Tempus. He is currently serving as Tempus’ CEO. Lefkofsky is also a big supporter of charities. In 2006, he founded the Lefkofsky Family Foundation, which seeks improve life in the communities the foundation serves. He also very active on behalf of the Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago, and the Steppenwolf Theatre Company.
To learn more, visit : Tempus.com/about-us